Inflammatix
6
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
1 terminated/withdrawn out of 6 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
Role: lead
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
Role: lead
Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)
Role: lead
Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial
Role: lead
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
Role: lead
Collection of Clinical Specimens From Volunteers for Assay Development
Role: lead
All 6 trials loaded